Cytokine secretion and NK cell activity in human ADAM17 deficiency

被引:30
|
作者
Tsukerman, Pinchas [1 ]
Eisenstein, Eli M. [2 ]
Chavkin, Maor [2 ]
Schmiedel, Dominik [1 ]
Wong, Eitan [3 ]
Werner, Marion [4 ]
Yaacov, Barak [4 ]
Averbuch, Diana [5 ]
Molho-Pessach, Vered [6 ]
Stepensky, Polina [7 ]
Kaynan, Noa [1 ]
Bar-On, Yotam [1 ]
Seidel, Einat [1 ]
Yamin, Rachel [1 ]
Sagi, Irit [3 ]
Elpeleg, Orly [4 ]
Mandelboim, Ofer [1 ]
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Sch, BioMed Res Inst, Lautenberg Ctr Gen & Tumor Immunol, IL-91010 Jerusalem, Israel
[2] Hadassah Hebrew Univ, Med Ctr, Dept Pediat, Mt Scopus, Jerusalem Il, Israel
[3] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel
[4] Hadassah Hebrew Univ, Med Ctr, Monique & Jacques Roboh Dept Genet Res, Jerusalem, Israel
[5] Hadassah Hebrew Univ, Med Ctr, Pediat Infect Dis Unit, Jerusalem, Israel
[6] Hadassah Hebrew Univ, Med Ctr, Dept Dermatol, Jerusalem, Israel
[7] Hadassah Hebrew Univ, Med Ctr, Pediat Hematooncol & Bone Marrow Transplantat Dep, Jerusalem, Israel
基金
欧洲研究理事会; 以色列科学基金会;
关键词
ADAM17; deficiency; NK cells; CD16; ADCC; Immunology and Microbiology Section; Immune response; Immunity; NATURAL-KILLER-CELLS; CD16; CYTOTOXICITY; INHIBITION; RECEPTORS; INFLAMMATION; ACTIVATION; FC; REGENERATION; STIMULATION;
D O I
10.18632/oncotarget.6629
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Genetic deficiencies provide insights into gene function in humans. Here we describe a patient with a very rare genetic deficiency of ADAM17. We show that the patient's PBMCs had impaired cytokine secretion in response to LPS stimulation, correlating with the clinical picture of severe bacteremia from which the patient suffered. ADAM17 was shown to cleave CD16, a major NK killer receptor. Functional analysis of patient's NK cells demonstrated that his NK cells express normal levels of activating receptors and maintain high surface levels of CD16 following mAb stimulation. Activation of individual NK cell receptors showed that the patient's NK cells are more potent when activated directly by CD16, albeit no difference was observed in Antibody Depedent Cytotoxicity (ADCC) assays. Our data suggest that ADAM17 inhibitors currently considered for clinical use to boost CD16 activity should be cautiously applied, as they might have severe side effects resulting from impaired cytokine secretion.
引用
收藏
页码:44151 / 44160
页数:10
相关论文
共 50 条
  • [31] Adam17 Deficiency Promotes Atherosclerosis by Enhanced TNFR2 Signaling in Mice
    Nicolaou, Alexandros
    Zhao, Zhen
    Northoff, Bernd H.
    Sass, Kristina
    Herbst, Andreas
    Kohlmaier, Alexander
    Chalaris, Athena
    Wolfrum, Christian
    Weber, Christian
    Steffens, Sabine
    Rose-John, Stefan
    Teupser, Daniel
    Holdt, Lesca M.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2017, 37 (02) : 247 - +
  • [32] Inhibition of ADAM17 impairs endothelial cell necroptosis and blocks metastasis
    Bolik, Julia
    Krause, Freia
    Stevanovic, Marija
    Gandrass, Monja
    Thomsen, Ilka
    Schacht, Sarah-Sophie
    Rieser, Eva
    Mueller, Miryam
    Schumacher, Neele
    Fritsch, Juergen
    Wichert, Rielana
    Galun, Eithan
    Bergmann, Juri
    Roeder, Christian
    Schafmayer, Clemens
    Egberts, Jan-Hendrik
    Becker-Pauly, Christoph
    Saftig, Paul
    Lucius, Ralph
    Schneider-Brachert, Wulf
    Barikbin, Roja
    Adam, Dieter
    Voss, Matthias
    Hitzl, Wolfgang
    Krueger, Achim
    Strilic, Boris
    Sagi, Irit
    Walczak, Henning
    Rose-John, Stefan
    Schmidt-Arras, Dirk
    JOURNAL OF EXPERIMENTAL MEDICINE, 2021, 219 (01):
  • [33] Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency
    Dosch, Joseph
    Ziemke, Elizabeth
    Wan, Shanshan
    Luker, Kathryn
    Welling, Theodore
    Hardiman, Karin
    Fearon, Eric
    Thomas, Suneetha
    Flynn, Matthew
    Rios-Doria, Jonathan
    Hollingsworth, Robert
    Herbst, Ronald
    Hurt, Elaine
    Sebolt-Leopold, Judith
    ONCOTARGET, 2017, 8 (39) : 65090 - 65099
  • [34] Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates
    Yoneyama, Toshie
    Gorry, Michael
    Miller, Miles A.
    Gaither-Davis, Autumn
    Lin, Yan
    Moss, Marcia L.
    Griffith, Linda G.
    Lauffenburger, Douglas A.
    Stabile, Laura P.
    Herman, James G.
    Vujanovic, Nikola L.
    JOURNAL OF CANCER, 2017, 8 (19): : 3916 - 3932
  • [35] Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity
    Halka Buryova
    Karel Chalupsky
    Olga Zbodakova
    Ivan Kanchev
    Marketa Jirouskova
    Martin Gregor
    Radislav Sedlacek
    BMC Gastroenterology, 13
  • [36] ADAM17 The new face of breast cancer-promoting metalloprotease activity
    Glunde, Kristine
    Stasinopoulos, Ioannis
    CANCER BIOLOGY & THERAPY, 2009, 8 (11) : 1055 - 1057
  • [37] The sheddase activity of ADAM17/TACE is regulated by the tetraspanin CD9
    Maria Dolores Gutiérrez-López
    Alvaro Gilsanz
    María Yáñez-Mó
    Susana Ovalle
    Esther M. Lafuente
    Carmen Domínguez
    Peter N. Monk
    Isidoro González-Alvaro
    Francisco Sánchez-Madrid
    Carlos Cabañas
    Cellular and Molecular Life Sciences, 2011, 68 : 3275 - 3292
  • [38] ADAM17 cytoplasmic domain modulates Thioredoxin-1 conformation and activity
    e Costa, Rute A. P.
    Granato, Daniela C.
    Trino, Luciana D.
    Yokoo, Sami
    Carnielli, Carolina M.
    Kawahara, Rebeca
    Domingues, Romenia R.
    Pauletti, Bianca Alves
    Neves, Leandro Xavier
    Santana, Aline G.
    Paulo, Joao A.
    Aragao, Annelize Z. B.
    Heleno Batista, Fernanda Aparecida
    Migliorini Figueira, Ana Carolina
    Laurindo, Francisco R. M.
    Fernandes, Denise
    Hansen, Hinrich P.
    Squina, Fabio
    Gygi, Steven P.
    Paes Leme, Adriana F.
    REDOX BIOLOGY, 2020, 37
  • [39] Differential Surface Expression of ADAM10 and ADAM17 on Human T Lymphocytes and Tumor Cells
    Ebsen, Henriette
    Schroeder, Alexandra
    Kabelitz, Dieter
    Janssen, Ottmar
    PLOS ONE, 2013, 8 (10):
  • [40] Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity
    Buryova, Halka
    Chalupsky, Karel
    Zbodakova, Olga
    Kanchev, Ivan
    Jirouskova, Marketa
    Gregor, Martin
    Sedlacek, Radislav
    BMC GASTROENTEROLOGY, 2013, 13